Vivaglobin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Multifocal Motor Neuropathy (MMN)
Conditions
Multifocal Motor Neuropathy (MMN)
Trial Timeline
Nov 1, 2007 → Jan 1, 2009
NCT ID
NCT00701662About Vivaglobin
Vivaglobin is a phase 2 stage product being developed by CSL for Multifocal Motor Neuropathy (MMN). The current trial status is completed. This product is registered under clinical trial identifier NCT00701662. Target conditions include Multifocal Motor Neuropathy (MMN).
What happened to similar drugs?
0 of 1 similar drugs in Multifocal Motor Neuropathy (MMN) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00701662 | Phase 2 | Completed |
| NCT00520494 | Approved | Completed |
Competing Products
7 competing products in Multifocal Motor Neuropathy (MMN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 35 |
| ARGX-117 | Argenx | Phase 2 | 36 |
| Empasiprubart + IVIG (Intravenous Immunoglobulin) | Argenx | Phase 3 | 44 |
| ARGX-117 | Argenx | Phase 2 | 32 |
| mefloquine | Biogen | Phase 1/2 | 21 |
| Tysabri | Biogen | Pre-clinical | 23 |
| HyQvia + Subcuvia | Baxter | Phase 2 | 32 |